Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating)'s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.57 and traded as low as $0.47. Aeglea BioTherapeutics shares last traded at $0.49, with a volume of 81,533 shares traded.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company raised shares of Aeglea BioTherapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $1.50 to $2.00 in a report on Friday, October 28th. StockNews.com assumed coverage on shares of Aeglea BioTherapeutics in a report on Monday, January 9th. They issued a "hold" rating on the stock. Finally, Piper Sandler increased their price target on shares of Aeglea BioTherapeutics to $1.50 in a report on Tuesday, November 1st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1.88.
Get Aeglea BioTherapeutics alerts:Aeglea BioTherapeutics Stock Up 2.7 %
The business's 50-day simple moving average is $0.57 and its 200 day simple moving average is $0.60. The firm has a market capitalization of $30.32 million, a P/E ratio of -0.43 and a beta of 1.66.
Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.05. Aeglea BioTherapeutics had a negative net margin of 1,471.82% and a negative return on equity of 114.95%. The business had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.63 million. Sell-side analysts predict that Aeglea BioTherapeutics, Inc. will post -1.01 earnings per share for the current year.Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Advisers LP grew its holdings in shares of Aeglea BioTherapeutics by 76.9% in the third quarter. Two Sigma Advisers LP now owns 409,900 shares of the biotechnology company's stock worth $216,000 after purchasing an additional 178,200 shares during the last quarter. Ghost Tree Capital LLC grew its holdings in shares of Aeglea BioTherapeutics by 8.1% in the third quarter. Ghost Tree Capital LLC now owns 1,000,000 shares of the biotechnology company's stock worth $526,000 after purchasing an additional 75,000 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Aeglea BioTherapeutics by 5.6% in the second quarter. Goldman Sachs Group Inc. now owns 1,187,293 shares of the biotechnology company's stock worth $600,000 after purchasing an additional 62,504 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Aeglea BioTherapeutics by 21.1% in the second quarter. Nantahala Capital Management LLC now owns 3,877,311 shares of the biotechnology company's stock worth $1,958,000 after purchasing an additional 676,718 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC grew its holdings in shares of Aeglea BioTherapeutics by 87.8% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 5,347,689 shares of the biotechnology company's stock worth $2,701,000 after purchasing an additional 2,500,000 shares during the last quarter. 78.01% of the stock is currently owned by institutional investors.
About Aeglea BioTherapeutics
(Get Rating)
Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
See Also
- Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.